AC Immune SA
Research AC Immune SA (ACIU) on Bullrun: market cap USD 266.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACIU
- ExchangeNASDAQ
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 266.01M
- Financial periodQ2 2026
- RevenueCHF 15.11M
- Net incomeCHF 1.87M
Valuation Snapshot
latest market cap is USD 266.01M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CHF 3.57M | -CHF 70.45M | -CHF 70.16M | n/a | -1.26 | CHF 26.80M | CHF 4.54M | CHF 44.88M |
| FY2024 | CHF 27.31M | -CHF 50.92M | CHF 65.27M | n/a | n/a | CHF 36.28M | CHF 5.43M | CHF 112.27M |
| FY2023 | n/a | n/a | n/a | n/a | -1.23 | CHF 78.49M | CHF 3.50M | CHF 160.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 266.01M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 319.47M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 271.11M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 494.01M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 170.16M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 413.22M | n/a | n/a | n/a |
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AC Immune SA's market cap?
AC Immune SA's market capitalization is USD 266.01M.
What does AC Immune SA do?
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.